To earn the NDI status, Aker BioMarine submitted human and animal data on scientific research and toxicology for Superba.
Superba Krill Oil has received New Dietary Ingredient (NDI) notification from FDA, according to its supplier Aker BioMarine (Oslo, Norway).
Krill oil is an emerging source of marine omega-3s eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and astaxanthin. Due to its low level on the food chain, krill is marketed as a nutrition source with low accumulation of heavy metals.
To earn the NDI status, Aker BioMarine submitted human and animal data on scientific research and toxicology for Superba.
“Krill oil has been legally marketed in the United States for many years,” says Nils Hoem, PhD, chief scientist at Aker BioMarine. “However, in addition to our GRAS submission already in place, we felt that our choice to submit information to FDA for review via the NDI process fully validates our safety dossier. Further, our unique manufacturing process uses ethanol, a more internationally accepted solvent.”
Superba Krill Oil is also the only krill ingredient bearing Marine Stewardship Council (MSC) Certification for sustainable fishing practices.
The Nutritional Outlook Podcast Episode 35: Prioritizing Women's Health Research and Innovation
October 28th 2024On this month's episode of the Nutritional Outlook Podcast, Cepham's founder and president, Anand Swaroop, discusses the company's recent announcement to prioritize women's health research and innovation.
The Nutritional Outlook Podcast Episode 34: Demystifying Prebiotics and Postbiotics
September 30th 2024In this episode of the Nutritional Outlook Podcast we are looking back on a webcast Nutritional Outlook hosted in May, called “Demystifying the Prebiotic and Postbiotic Markets.” During that event, Sandra Saville, director of education and communication for the International Probiotics Association and Dr. Jessica A. Younes, scientific director of the International Probiotics Association debunked myths about prebiotic and postbiotics, and defined the respective categories to help manufacturers better understand how to responsibly formulate and market prebiotic and postbiotic products.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.